S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Arkhouse and Brigade up Macy's takeover offer to $6.6 billion following rejection of previous deal
One company did the impossible with AI (Ad)
OPEC+ production cuts deepen with extensions from Saudi Arabia, Russia and other oil giants
Stock market today: Japan's Nikkei tops 40,000, as investors await China political meeting
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Arkhouse and Brigade up Macy's takeover offer to $6.6 billion following rejection of previous deal
One company did the impossible with AI (Ad)
OPEC+ production cuts deepen with extensions from Saudi Arabia, Russia and other oil giants
Stock market today: Japan's Nikkei tops 40,000, as investors await China political meeting
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Arkhouse and Brigade up Macy's takeover offer to $6.6 billion following rejection of previous deal
One company did the impossible with AI (Ad)
OPEC+ production cuts deepen with extensions from Saudi Arabia, Russia and other oil giants
Stock market today: Japan's Nikkei tops 40,000, as investors await China political meeting
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Arkhouse and Brigade up Macy's takeover offer to $6.6 billion following rejection of previous deal
One company did the impossible with AI (Ad)
OPEC+ production cuts deepen with extensions from Saudi Arabia, Russia and other oil giants
Stock market today: Japan's Nikkei tops 40,000, as investors await China political meeting
NYSE:ZYME

Zymeworks (ZYME) Stock Price, News & Analysis

$12.51
+0.50 (+4.16%)
(As of 03/1/2024 ET)
Today's Range
$11.92
$12.55
50-Day Range
$9.83
$12.90
52-Week Range
$6.01
$13.14
Volume
434,425 shs
Average Volume
469,850 shs
Market Capitalization
$875.70 million
P/E Ratio
4.02
Dividend Yield
N/A
Price Target
$13.67

Zymeworks MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
9.2% Upside
$13.67 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.09mentions of Zymeworks in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$436,264 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.96) to ($1.24) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.69 out of 5 stars

Medical Sector

861st out of 947 stocks

Pharmaceutical Preparations Industry

401st out of 437 stocks

ZYME stock logo

About Zymeworks Stock (NYSE:ZYME)

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, colorectal, and endometrial cancers; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

ZYME Stock Price History

ZYME Stock News Headlines

Zymeworks (ZYME) Scheduled to Post Earnings on Wednesday
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
ZYME Apr 2024 10.000 put
ZYME Jul 2024 7.500 put
Should Investors Get Jazzed Up About This Small-Cap Biotech?
Last Call! 7 Small-Cap Stocks Ready to Explode in Value
ZYME Mar 2024 15.000 call
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Zymeworks Inc. (ZYME)
Zymeworks Inc CEO Kenneth Galbraith Sells 23,904 Shares
Zymeworks lays out 2024 and 2025 outlook
Zymeworks Announces Additional Leadership Appointments
See More Headlines
Receive ZYME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2021
Today
3/03/2024
Next Earnings (Confirmed)
3/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Previous Symbol
NASDAQ:ZYME
Employees
252
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.67
High Stock Price Target
$19.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+9.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$124.34 million
Pretax Margin
47.75%

Debt

Sales & Book Value

Annual Sales
$412.48 million
Cash Flow
$2.16 per share
Book Value
$7.82 per share

Miscellaneous

Free Float
69,148,000
Market Cap
$875.70 million
Optionable
Optionable
Beta
1.16
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Kenneth H. Galbraith C.A. (Age 61)
    CEO & Chairman of the Board
    Comp: $1.22M
  • Dr. Christopher Astle Ph.D. (Age 44)
    Senior VP & CFO
    Comp: $721.23k
  • Mr. Mark Hollywood (Age 54)
    Executive VP and Head of Technical & Manufacturing Operations
  • Dr. Paul Moore Ph.D. (Age 57)
    Chief Scientific Officer
  • Jack W. Spinks
    Associate Director of Investor Relations
  • Mr. Daniel Dex J.D.
    Ph.D., Senior VP, Corporate Secretary & General Counsel
  • Diana Papove
    Senior Manager of Corporate Communications
  • Dr. Lindsey Foulkes B.Sc.
    Ph.D., Vice President of Corporate Development
  • Ms. Laura O'Connor
    Vice President of Human Resources & DEI
  • Dr. Jeffrey Smith M.D.
    Executive VP & Chief Medical Officer














ZYME Stock Analysis - Frequently Asked Questions

Should I buy or sell Zymeworks stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ZYME shares.
View ZYME analyst ratings
or view top-rated stocks.

What is Zymeworks' stock price target for 2024?

4 Wall Street research analysts have issued 12-month price objectives for Zymeworks' shares. Their ZYME share price targets range from $8.00 to $19.00. On average, they anticipate the company's stock price to reach $13.67 in the next year. This suggests a possible upside of 9.2% from the stock's current price.
View analysts price targets for ZYME
or view top-rated stocks among Wall Street analysts.

How have ZYME shares performed in 2024?

Zymeworks' stock was trading at $10.39 on January 1st, 2024. Since then, ZYME shares have increased by 20.4% and is now trading at $12.51.
View the best growth stocks for 2024 here
.

When is Zymeworks' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our ZYME earnings forecast
.

How can I listen to Zymeworks' earnings call?

Zymeworks will be holding an earnings conference call on Wednesday, March 6th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Zymeworks' earnings last quarter?

Zymeworks Inc. (NYSE:ZYME) announced its quarterly earnings data on Wednesday, November, 3rd. The company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($1.17) by $0.08. The business earned $4.40 million during the quarter, compared to the consensus estimate of $8.80 million. Zymeworks had a trailing twelve-month return on equity of 44.62% and a net margin of 44.47%.

What ETF holds Zymeworks' stock ?

Invesco Russell 2000 Dynamic Multifactor ETF holds 148,747 shares of ZYME stock, representing 0.32% of its portfolio.

What is Ali Tehrani's approval rating as Zymeworks' CEO?

9 employees have rated Zymeworks Chief Executive Officer Ali Tehrani on Glassdoor.com. Ali Tehrani has an approval rating of 100% among the company's employees. This puts Ali Tehrani in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Zymeworks to a friend.

What other stocks do shareholders of Zymeworks own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Just Energy Group (JE), NVIDIA (NVDA), Just Energy Group (JE), PayPal (PYPL), Alibaba Group (BABA), Cronos Group (CRON), CRISPR Therapeutics (CRSP) and Tesla (TSLA).

When did Zymeworks IPO?

(ZYME) raised $65 million in an IPO on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity served as the underwriters for the IPO and Cormark Securities was co-manager.

Who are Zymeworks' major shareholders?

Zymeworks' stock is owned by a variety of retail and institutional investors. Top institutional investors include Rubric Capital Management LP (4.96%), Vanguard Group Inc. (3.42%), Perceptive Advisors LLC (1.54%), Granahan Investment Management LLC (1.00%), Bridgeway Capital Management LLC (0.97%) and Northern Trust Corp (0.60%). Insiders that own company stock include Ali Tehrani, Christopher Astle, Ecor1 Capital, Llc, James Priour, Kathryn O'driscoll, Kenneth Galbraith, Neil A Klompas, Neil Josephson and Paul Andrew Moore.
View institutional ownership trends
.

How do I buy shares of Zymeworks?

Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ZYME) was last updated on 3/3/2024 by MarketBeat.com Staff

From Our Partners